ABBVIE INC | 32,30 Euro | +0,055 +0,17 % | |
| WKN: A1J84E ISIN: US00287Y1091 Ticker-Symbol: 4AB | Frankfurt | 20.06.13 | 09:49 Uhr |
Branche PharmaAktienmarkt S&P 100S&P 500 |
|
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 17.06. | Successor To Humira? Abbvie And Galapagos Work On It | 8 | Seeking Alpha | |
| 17.06. | Data on BMY/ AbbVie's elotuzumab | 5 | Zacks | |
| 17.06. | AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting | 9 | PR Newswire | |
| NORTH CHICAGO, Ill., June 17, 2013 /PRNewswire/ --AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective... Mehr lesen zu: AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting | ||||
| 15.06. | Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study | 4 | Benzinga.com | |
| 15.06. | Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma | 10 | Business Wire | |
| Median progression-free survival (PFS) of 33 months reached after longer-term follow up in patients treated with elotuzumab 10 mg/kg plus lenalidomide and low-dose dexamethasone ... Mehr lesen zu: Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma | ||||
| 14.06. | AbbVie's Management Presents at Goldman Sachs 34th Annual Global Healthcare Conference - Transcript | 3 | Seeking Alpha | |
| 13.06. | AbbVie Says It Can Be First With New Hepatitis C Drugs | 8 | Bloomberg | |
| 13.06. | AbbVie Announces Positive Results from Concerto Trial | 6 | Benzinga.com | |
| 13.06. | AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA (adalimumab) for Rheumatoid Arthritis | 15 | PR Newswire | |
| MADRID, June 13, 2013 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate... Mehr lesen zu: AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA (adalimumab) for Rheumatoid Arthritis | ||||
| 12.06. | Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and GlaxoSmithKline | 34 | PR Newswire | |
| NEW YORK, June 12, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Wall Street Reports announced new research reports highlighting Johnson... Mehr lesen zu: Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and GlaxoSmithKline | ||||
| 05.06. | AbbVie Pharmaceuticals - High Risk With Little Upside Potential | 21 | Seeking Alpha | |
| 05.06. | AbbVie to Participate in 34th Annual Goldman Sachs Global Healthcare Conference | 43 | PR Newswire | |
| NORTH CHICAGO, Ill., June 5, 2013 /PRNewswire/ --AbbVie (NYSE: ABBV) will participate in the 34th Annual Goldman Sachs Global Healthcare Conference on Thursday, June 13, 2013. Bill Chase, executive... Mehr lesen zu: AbbVie to Participate in 34th Annual Goldman Sachs Global Healthcare Conference | ||||
| 03.06. | AbbVie (ABBV) Issues Phase 1 Results for ABT-199 on CLL | 7 | StreetInsider.com | |
| 03.06. | AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting | 51 | PR Newswire | |
| NORTH CHICAGO, Ill., June 3, 2013 /PRNewswire/ --AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for... Mehr lesen zu: AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting | ||||
| 03.06. | For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders' Opinions Indicate that AbbVie/Eisai's Humira Has the Best Clinical Profile Among Key Marketed Therapies | 37 | PR Newswire | |
| BURLINGTON, Mass., June 3, 2013 /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that based on clinical data... Mehr lesen zu: For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders' Opinions Indicate that AbbVie/Eisai's Humira Has the Best Clinical Profile Among Key Marketed Therapies | ||||
| 31.05. | AbbVie's Creon delayed-release capsules available at higher dose in US | 5 | Pharma Bus Review | |
| 31.05. | Ask a Fool: What Do You Think About AbbVie? | 14 | Motley Fool | |
| 31.05. | AbbVie Ups Ante on JAK Inhibitor | 9 | Motley Fool | |
| 30.05. | UPDATE: AbbVie Announces Market Availability of New CREON® (pancrelipase) 36K Lipase-unit Capsules for Patients with Exocrine Pancreatic Insufficiency | 4 | Benzinga.com | |
| 30.05. | AbbVie Announces Market Availability of New CREON (pancrelipase) 36,000 Lipase-unit Capsules for Patients with Exocrine Pancreatic Insufficiency | 51 | PR Newswire | |
| NORTH CHICAGO, Ill., May 30, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that a new, higher-dose capsule of CREON® (pancrelipase) Delayed-Release Capsules is commercially available in... Mehr lesen zu: AbbVie Announces Market Availability of New CREON (pancrelipase) 36,000 Lipase-unit Capsules for Patients with Exocrine Pancreatic Insufficiency | ||||
Seite: 1 2 3 4 5 ... Weiter >>
191 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von